Highlights Sanofi

Equities

SAN

FR0000120578

Pharmaceuticals

Market Closed - Euronext Paris Other stock markets 16:37:24 29/11/2024 GMT			5-day change	1st Jan Change
92.09 ^EUR	-0.01%		-1.16%	+2.60%

11-29	Astrazeneca's Enhertu, Orpathys Among 91 Drugs Added to China's National Reimbursement Drug List	MT
11-29	Intron Health Downgrades Sanofi to Hold, Lowers PT	MT

Highlights

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Astrazeneca's Enhertu, Orpathys Among 91 Drugs Added to China's National Reimbursement Drug List	11-29	MT
Sanofi Opens Second Manufacturing Plant in Singapore	11-28	MT
Sanofi Opens New $600 Million Vaccines Facility in Singapore	11-27	MT
NSC Sanofi and A*STAR Enter Agreement to Further Research on Acne Treatment	11-26	MT
AlphaValue/Baader Europe Upgrades Sanofi to Buy, Trims PT	11-21	MT
Sanofi to Invest EUR40 Million in French Bioproduction Site	11-15	MT
Sanofi invests 40 ME in its Lyon Gerland site	11-15	CF
Conference on the future of type 1 diabetes screening coordinated by Diamyd	11-15	FW
US FDA Accepts Revised Application for Sanofi's Inflammatory Skin Disease Drug	11-15	MT
Regeneron Pharmaceuticals, Inc. and Sanofi Announces U.S. Food and Drug Administration Accepts for Review the Resubmission of the Supplemental Biologics License Application for Dupixent®?	11-15	CI
EMA Committee Recommends EU Approval of Sanofi's Sarclisa for Multiple Myeloma Treatment	11-15	MT
Healx Announces Agreement with Sanofi to Seek New Rare Disease Indications for Compound Using AI Drug Discovery Platform	11-13	CI
Novavax cuts 2024 revenue forecast again on lower COVID vaccine sales	11-12	RE
Formation Bio Collaborates with OpenAI and Sanofi to Introduce Muse	11-12	CI
Novavax to Move Forward With Covid-19-Flu Vaccine After FDA Lifts Clinical Hold -- Update	11-11	DJ
Italy's Recordati sees no impact from potential US pharma tariffs	11-08	RE
Regeneron Pharmaceuticals, Inc. and Sanofi Receive European Union Approval For Dupixent In Young Children With Eosinophilic Esophagitis	11-06	CI
Regeneron beats results estimates on demand for eczema treatment, eye drug	10-31	RE
Sanofi Partners with SandboxAQ on AI-Driven Drug Discovery	10-29	MT
SANOFI : UBS reiterates its buy recommendation	10-29	CF
Lifecare AS Announces the Finalization of A New Development Phase Under the Product Development Agreement with Sanofi	10-29	CI
Lifecare to Submit Phase-end Report Under Product Development Deal to Sanofi	10-29	MT
Sanofi Announces Beyfortus to Be Broadly Available for Babies Born in Ontario, Quebec, Nunavut, Northwest Territories, and the Yukon This Fall	10-28	CI
AbbVie to Acquire Aliada Therapeutics for $1.4 Billion -- Update	10-28	DJ
Sanofi Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024	10-25	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

SANOFI : Q3 beat; all eyes now on the innovative pharma business promises

October 25, 2024 at 01:59 pm

Sanofi : The Doliprane case

October 18, 2024 at 02:16 pm

Paul Hudson, CEO of Sanofi: AI to improve organisational efficiency

July 03, 2024 at 09:01 pm